NIFTY 50

2021 will be good for pharma like Divis, Sun Pharma, Ajanta, says MOFSL’s Gautam Duggad

Updated : December 30, 2020 11:55:53 IST

2021 will be a good year for the pharma sector, said Gautam Duggad, Head of Research-Institutional Equities at Motilal Oswal Financial Services on Wednesday.

Speaking with CNBC-TV18, he said, “We are projecting 35-40 percent earnings growth in Q3 of FY21 itself for pharma universe. We like Divis in this space, we continue to have Sun and Lupin in our model portfolio and we also like Ajanta Pharma, Granules. Therefore, I am excited about pharma as far as earnings are concerned for the next 2 years. Things seem to have turned around well in FY21 and they are expected to do well even in FY22.”

According to him, banking and financial companies will be the big theme of 2021.

“Banking will continue to surprise people in 2021. It has already given strong returns in the last 6 months. The other theme I remain bullish about in India and 2021 will see further glimpses of that is consumption," he added.

Duggad expects urban consumption to make a strong comeback.

For more details, watch the video
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you